Regulatory 2022-12-02 | Nomination Committee appointed for AGM 2023 in Ascelia Pharma AB PDF Report Presentation Webcast
2022-11-30 | ASCELIA PHARMA PRESENTS RESULTS OF ORVIGLANCE FOOD EFFECT STUDY AT RSNA 2022 SHOWING STRONG LIVER ENHANCEMENT BOTH WITH LIGHT MEAL AND IN FASTING CONDITION PDF Report Presentation Webcast
2022-09-28 | Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study PDF Report Presentation Webcast
2022-08-11 | Ascelia Pharma to present Orviglance Food Effect Study at 2022 RSNA Annual Meeting PDF Report Presentation Webcast
2022-06-20 | Ascelia Pharma appoints Déspina Georgiadou Hedin as new CFO PDF Report Presentation Webcast
2022-06-01 | Results from Orviglance comparison study to gadolinium presented at ESGAR 2022 conference PDF PDF Report Presentation Webcast
2022-05-31 | Ascelia Pharma second US patent for Oncoral (oral irinotecan) strengthens coverage PDF Report Presentation Webcast
2022-05-10 | Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal PDF Report Presentation Webcast
Regulatory 2022-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022 PDF Report Presentation Webcast
Regulatory 2022-04-05 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
2022-03-22 | New independent market research says 84% US healthcare professionals likely to use Orviglance imaging agent in target population PDF PDF Report Presentation Webcast
2022-03-11 | Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study PDF Report Presentation Webcast
Regulatory 2022-03-07 | Ascelia Pharma suspends clinical activities in Russia PDF Report Presentation Webcast
2022-03-02 | Issue and repurchase of series C shares for share saving program PDF Report Presentation Webcast
2022-02-15 | Results from Orviglance comparison study to gadolinium accepted for oral presentation at the ESGAR conference PDF Report Presentation Webcast
2021-12-16 | Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial PDF Report Presentation Webcast
